Article
Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Aug 2023
Rotow Julia, Patel Jyoti D, Hanley Matthew P, Yu Helena, Awad Mark, Goldman Jonathan W, Nechushtan Hovav, Scheffler Matthias, Kuo Chih-Hsi S, Rajappa Senthil, Harada Guilherme, Clifford Sarah, Santucci Alison, Silva Laura, Tupper Rebecca, Oxnard Geoffrey R, Kherani Jennifer, Drilon Alexander
Abstract excerpt
PURPOSE: Acquired RET fusions have been reported at resistance to treatment with EGFR inhibitors in EGFR-mutant non-small cell lung cancer (NSCLC); however, a multicenter cohort of patients with EGFR-mutant lung cancers treated with osimertinib and selpercatinib for RET fusion-mediated osimertinib resistance has not previously been published. PATIENTS AND METHODS: Patients who received selpercatinib in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.